Jalra-OD 100mg Tablet SR contains Vildagliptin 100mg, a potent oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon levels in a glucose-dependent manner. This mechanism helps to improve glycemic control without causing significant hypoglycemia or weight gain. Jalra-OD 100mg Tablet SR is formulated as a sustained-release preparation, ensuring a steady release of the active ingredient, which supports once-daily dosing and improves patient compliance. It is indicated as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas when diet and exercise alone do not provide adequate glycemic control. The drug is generally well tolerated, with common adverse effects including mild gastrointestinal disturbances and headache. Caution is advised in patients with renal or hepatic impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose levels and periodic assessment of renal function are recommended during therapy. Jalra-OD 100mg Tablet SR offers an effective and convenient option for long-term management of type 2 diabetes mellitus.